What is HC Wainwright’s Forecast for Entera Bio Q3 Earnings?

Entera Bio Ltd. (NASDAQ:ENTX) – Investment analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Entera Bio in a research note issued on Monday, August 11th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.09) per share for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for Entera Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Entera Bio’s Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.32) EPS.

Entera Bio Stock Performance

NASDAQ:ENTX opened at $2.00 on Thursday. The stock has a market capitalization of $91.32 million, a P/E ratio of -7.69 and a beta of 1.52. The company has a 50 day moving average price of $1.95 and a 200 day moving average price of $1.99. Entera Bio has a fifty-two week low of $1.50 and a fifty-two week high of $2.79.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.05. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 77.75%.

Hedge Funds Weigh In On Entera Bio

Hedge funds have recently made changes to their positions in the stock. HighTower Advisors LLC boosted its position in shares of Entera Bio by 53.3% during the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock worth $31,000 after purchasing an additional 6,310 shares during the period. Bessemer Group Inc. purchased a new position in Entera Bio in the 2nd quarter valued at approximately $268,000. Northern Trust Corp purchased a new position in Entera Bio in the 4th quarter valued at approximately $450,000. Parkman Healthcare Partners LLC boosted its position in Entera Bio by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock valued at $747,000 after buying an additional 25,900 shares during the period. Finally, Knoll Capital Management LLC boosted its position in Entera Bio by 51.5% in the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock valued at $12,470,000 after buying an additional 2,000,000 shares during the period. Hedge funds and other institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.